Australian regulator the Therapeutic Goods Administration (TGA) says that its investigation into the risk of myocardial infarction and stroke in patients taking romosozumab (Evenity) found that stronger warnings regarding these risks were needed in the Product Information (PI) and Consumer Medicine (CMI) Information external sites.
Marketed globally by Belgium’s UCB (Euronext: UCB) and US biotech Amgen (Nasdaq: AMGN), in Australia, romosozumab use is now also contraindicated in patients with a history of myocardial infarction or stroke.
The following sections of these documents have been updated to reflect an increased risk of myocardial infarction and stroke: Contraindications; Special warning and precautions for use; and Adverse events.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze